Verastem Oncology Doses First Participant In Its TARGET-D 203 Phase 2 Study Of VS-7375 To Treat Metastatic Colorectal Cancer
Verastem Inc VSTM
$5.80
▼ -4.92%
($-0.30)
🔥 High Short Interest
📅 Earnings This Week
Open
$6.04
Prev Close
$6.10
Day Range
$5.54 – $6.09
52W Range
$3.43 – $11.25
Market Cap
$529.00M
Beta
0.38
EPS (TTM)
$-2.51
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2011-11-08 |
| Shares Out. | 87,870,000 |
| Website | verastem.com/ ↗ |
| Phone | 13026587581 |
| Employees | 102 |
| Revenue | $18.7M |
| Gross Profit | $15.6M |
| Net Income | -$36.6M |
| Total Assets | $227.8M |
| Total Liabilities | $146.0M |
| Equity | $81.8M |
About Verastem Inc
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Verastem Inc is a publicly traded company under the ticker symbol VSTM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)
📰 Latest News for VSTM
12 Health Care Stocks Moving In Thursday's After-Market Session
Verastem Oncology Doses First Patient In Phase 2 Trial Of VS-7375 For KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer And Untreated Asymptomatic Untreated Brain Metastases
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why